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Seton Hall Law

Clinical Trials in Developing Countries
Michael W. Jacobson1
Introduction
The global pharmaceutical industry is a trillion dollar business.2 The foundation of the
pharmaceutical industry is built on developing new drugs for regulatory approval to be sold to
people all over the world.3 The United States is the largest pharmaceutical market in the world
and companies rely on having new products approved for sale in the United States. 4 The last
decade in the United States saw the number of newly approved drugs by the Federal Drug
Administration (“FDA”) decline and fail to keep pace with the increase in the amount of money
spent to research and develop new drugs. 5 The result has been research and development
spending becoming an area where pharmaceutical companies are increasingly looking to lower
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IMS Health Study Forecasts Global Spending on Medicines to Reach $1 Trillion Threshold in
2014, Driven by Greater Access, IMSHEALTH (Nov. 19, 2013),
http://www.imshealth.com/portal/site/imshealth/menuitem.c76283e8bf81e98f53c753c71ad8c22a
/?vgnextoid=96bdd595ae072410VgnVCM10000076192ca2RCRD.
3
Id., (“Growth Expected to Accelerate from Low Point in 2013 To 5-7 Percent in 2017; Rising
Number of Innovative New Drugs Expected To be Approved Over Next Five Years ”)
4
See Top Line Market Data, Press Room, IMSHEALTH (Mar. 19, 2013)
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/Press%20Room/2
012_U.S/Channel_Distribution_by_Non-Discounted_Spending_U.S.pdf (United States
pharmaceutical market in 2012 was $325.8 Billion); see Top Line Market Data, Press Room,
IMSHEALTH (June 2013),
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/Press%20Room/T
otal_World_Pharma_Market_Topline_metrics_2012-17_regions.pdf, (the United States and
Canada combined in 2012 was the largest region in the world at $348.7, next largest region was
Europe at $221.8 Billion).
5
See Evolution or revolution? McKinsey perspectives on drug and device R&D, (August 2012),
available at
http://www.mckinsey.com/insights/health_systems_and_services/restoring_value_to_biopharma
ceutical_r_and_38d; See also AJAY DHANKHAR ET AL., Escaping the sword of Damocles:
Toward a New Future for Pharmaceutical R&D, (August 2012), (“Restoring value to
biopharmaceutical R&D: After years of seeing value destroyed by R&D excesses,
biopharmaceutical companies can gain healthier returns—but only if they recognize several new
imperatives”).
2
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their costs.6 The low return on investments, the lack of available research subjects and the high
costs of clinical trials has led companies to conduct a majority of clinical trials outside of the
United States, including in developing countries.7
With more clinical trials occurring outside the United States, and the United States
accounting for more than a third of the total pharmaceutical market, public concern in the United
States has increased.8 The concern is two-fold. The first concern is the increased vulnerability
for human research subjects in clinical trials located in developing countries where regulatory
enforcement is weak. 9

The second concern is how the weak regulatory systems at the trial

location increases the potential for a product reaching the market based on invalid clinical trial
data.10

6

Dhankar, supra note 5, at 5; See also Gardiner Harris, F.D.A. Officials, Hoping to Stave Off
Critics, Point to Increased Drug Approvals, N.Y.TIMES, November 3, 2011, at A18, (“increase
in drug approvals is good news for the pharmaceutical and biotechnology industries, which
have failed to produce many new drugs in recent years. New drug approvals peaked in the
mid-1990s and have generally declined since then despite increases in research spending.
Major drug makers have steadily cut their research spending since 2008 because of poor
productivity.”).
7
Dep’t of Health & Human Serv., OEI-01-08-00510, Challenges to FDA’s Ability to Monitor
and Inspect Foreign Clinical Trials, 2 (June 2010), [hereinafter 2010 HHS OIG Report].
8
See Donald L. Bartlett & James B. Steele, Deadly Medicine, VANITY FAIR, (Jan. 2011),
http://www.vanityfair.com/politics/features/2011/01/deadly-medicine-201101 (discussing if the
number of people killed by prescriptions drugs in the United States will increase because of the
weak regulation at clinical trial locations in developing countries); See also, Talea Miller,
‘Explosive’ Growth in Foreign Drug Testing Raises Ethical Questions, PBS NEWSHOUR, (Aug.
23, 2011, 2:46 PM), http://www.pbs.org/newshour/rundown/sending-us-drug-research-overseas/,
(discussing the appeal of holding clinical trials in developing countries and the ethical issues
raised by this research trend); See generally The Body Hunters, WASHINGTON POST,
http://www.washingtonpost.com/wp-dyn/world/issues/bodyhunters/ (last visited March, 28,
2014) (“In this six-part series, the Post examines the booming, poorly- regulated system of
international clinical drug testing that far too often preys on the poor and uneducated and betrays
its promises to patients and consumers.”).
9
See supra note 8 and accompanying text.
10
See supra note 8 and accompanying text.
3

The FDA requires clinical trials conducted outside of the United States to be conducted in
accordance with Good Clinical Practice (GCP) and adhere to the local regulations. 11 Local
regulatory agencies in developing countries similarly require GCP be followed.12 Despite the
proliferation in regulation from the FDA and in developing countries, the current approach
leaves clinical trial participants in developing countries vulnerable to abuse and opens up
individuals to harm around the world that take a pharmaceutical drug that was approved based on
invalid data.13 The main problem in clinical trial research in developing countries is the inability
of the FDA to provide adequate oversight and the reliance on local regulatory agencies to
enforce the law.14
This paper argues that a three-prong approach involving the enforcement of existing FDA
regulations, the creation of international partnerships between regulatory bodies, and the
development of private peer-to-peer partnerships between pharmaceutical companies can work
together to prevent harm to research subjects in the developing world and stop harmful drugs
from being approved based on invalid clinical trials. Each stakeholder can work together using
21 C.F.R. § 312.120 (2013), (“For the purposes of this section, GCP is defined as a standard
for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of
clinical trials in a way that provides assurance that the data and reported results are credible and
accurate and that the rights, safety, and well-being of trial subjects are protected. GCP includes
review and approval (or provision of a favorable opinion) by an independent ethics committee
(IEC) before initiating a study, continuing review of an ongoing study by an IEC, and obtaining
and documenting the freely given informed consent of the subject (or a subject's legally
authorized representative, if the subject is unable to provide informed consent) before initiating a
study…and (ii) FDA is able to validate the data from the study through an onsite inspection if the
agency deems it necessary.”).
12
Daniel Liu, Good Clinical Practice-Compliant Clinical Studies in China, PHARMAFOCUSASIA
http://www.pharmafocusasia.com/research_development/good-clinical-practice-CompliantClinical-Studies-China.htm (last visited May 7, 2014); The Drugs and Cosmetics Rules, 1945 (as
amended up to the June 30th, 2005) [hereinafter Drug and Cosmetics], available at http://
cdsco.nic.in/html/Drugs&CosmeticAct.pdf.
13
See supra note 8 and accompanying text.
14
Gardiner Harris, Concern Over Foreign Trials for Drugs Sold in U.S., N.Y.TIMES, June 22,
2010, at A14.
11
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past safety and ethical issues involving clinical trial research on human subjects, to prevent a
reoccurrence of past behavior.15
Part one of this paper provides an overview of the clinical trial process, the market forces
that have shifted the geographical footprint of clinical trials, where the clinical trial market is
going and the current FDA regulation of domestic clinical trials, data from clinical trials
conducted in developing countries. Part two looks at international regulations and the rise of
clinical trials in China and India to illustrate international regulation of clinical trials in
developing countries, the opaque information surrounding clinical trials in developing countries,
its impact on the FDA and United States market.16 Part three proposes a three-prong solution to
address the ethical and safety questions for the stakeholders involved.
I. The Clinical Trial Market
A. Clinical Trials in The United States
The development of a new drug for approval in the United States by the FDA requires the
submission of clinical trial data displaying the efficacy and safety of the new drug.17 This is the
end point of the clinical trial process. To get to this point a company has to navigate a process

15

How Tuskegee Changed Research Practice, CDC http://www.cdc.gov/tuskegee/after.htm (last
updated Sept. 24, 2013).
16
To properly illustrate and analyze the problem of ethical research of human subjects in
developing countries and the effect on product users around the globe I selected countries that
have seen tremendous growth in their clinical trial market, have increased regulation as result of
the growth, and what the effect has been on research subjects and product users.
17
21 C.F.R. § 314.50 (2013) (“A description and analysis of any other data or information
relevant to an evaluation of the safety and effectiveness of the drug product obtained or
otherwise received by the applicant from any source, foreign or domestic, including information
derived from clinical investigations, including controlled and uncontrolled studies of uses of the
drug other than those proposed in the application, commercial marketing experience, reports in
the scientific literature, and unpublished scientific papers.”).
5

that is lengthy, heavily regulated, and is dependent on the availability of research subjects who
are willing to participate in the clinical trial process.18
The clinical process begins with clinical testing on animals and then submission of an
investigational new drug (IND) application to the FDA.19 The IND contains information for the
proposed human testing from the sponsor of the clinical trial.20 The IND is then reviewed by the
FDA for approval.21 Institutional Review Boards (IRB) play the part of making sure that the
proposed study is acceptable based on the clinical trial protocols proposed by the sponsor, the
protection of research subjects and the information available to potential research subjects.22
Following IND approval, phase I trials can begin. Phase I trials are conducted on twenty
to eighty healthy research subjects and are designed to determine the side effects, and the rate in
which the drug is metabolized and excreted. 23 Phase II trials focus on research subjects who
suffer from the ailment that the drug is designed to target and usually contain research subjects
numbering in the double digits to three hundred.24 If phase II trials indicate that the drug is
effective, phase III trials can begin. 25 Phase III trials focus on the safety and efficacy of the drug
across various populations, different dosage levels, and how the drug interacts with other
medications.26 Phase III trials can include research subjects that number in the thousands.27

18

See Joseph A. DiMasi, et al., The Price of Innovation: New Estimates of Drug Development
Costs, 22 J. HEALTH ECON. 151 (2003).
19
21 C.F.R. § 312 (2013); see also The FDA's Drug Review Process: Ensuring Drugs Are Safe
and Effective, FDA.GOV,
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.htm (last updated Apr. 25,
2014) (provides a simplified overview of the drug review process).
20
See supra note 19 and accompanying text.
21
Id.
22
Id.
23
Id.
24
Id.
25
Id.
26
Id.
6

The next step is for the sponsor to submit a new drug application (NDA) to the FDA that
contains the information from the clinical trial results and relevant analyses.28 At this point the
FDA can reject, approve or request further information based on the NDA submitted.29 With the
average cost of bringing a new drug to market estimated to be between $800 million and in
excess of five billion dollars, the decisions made during the clinical process have huge financial
impact.30 The time period from preclinical testing to approval is estimated to take ten to fifteen
years on average.31 At the completion of each phase the decision must be made on whether to
move the product to the next phase or to abandon the research. The R&D costs increase as a
product moves along the drug discovery process.32 The prospect of failure also increases at each
phase of the drug discovery process.33 Successful trials are abandoned if the product being tested
is not projected to cover its research costs and provide a return for the company.34
IND applications are not required for clinical trials that are conducted entirely outside the
United States.35 Further, sponsors can submit a NDA based solely on clinical trial data from
outside the United States that was never subjected to an IND approval. 36 Only after the trials are

27

Id.
See supra note 17 and accompanying text.
29
See supra note 19 and accompanying text.
30
DiMasi, supra note 18 at 173; Matthew Harper, The Cost Of Creating A New Drug Now $5
Billion, Pushing Big Pharma To Change, FORBES (Aug. 11, 2013, 11:10AM),
http://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventingnew-drugs-is-shaping-the-future-of-medicine/.
31
Pharmaceutical Research and Manufacturers of America, 2013 Biopharmaceutical Research
Industry Profile, (July 2013),
http://www.phrma.org/sites/default/files/pdf/PhRMA%20Profile%202013.pdf.
32
Fabio Pammolli, et al., The productivity crisis in pharmaceutical R&D, NATURE (June 2011),
http://www.nature.com/nrd/journal/v10/n6/fig_tab/nrd3405_F1.html.
33
Id. at figure 2 (showing the increase in attrition rates at each phase).
34
Harper, supra note 30 (quoting Roger Perlmutter, head of Merck R&D, saying, “One common
mistake is allowing projects to linger on when the odds of success have become low”).
35
21 C.F.R. 312.120 (2013); OIG FOREIGN CLINICAL TRIALS REPORT supra note 7, at 2;
36
21 C.F.R. § 312.120 (2013); 21 C.F.R. § 314.106 (2013).
28
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concluded does the FDA require that sponsors submit information that the study was conducted
in line with GCP showing the qualifications of the clinical investigators, review of the trial by an
independent committee and summary of adherence to the ethical protocols.37 The relationship
between foreign regulatory authorities and the FDA is often unbalanced. 38 In developing
countries the disparity is even greater.39 This is perhaps the most unique problem facing the FDA
as they increasingly rely on regulatory bodies outside the United States and in developing
countries.
B. Clinical Trial Regulation in The United States and The Acceptance of Foreign Data
The protection of research subjects participating in clinical trials in the United States
began with the passing of the National Research Act in 1974 establishing the National
Commission for the Protection of Human Subjects in Biomedical and Behavioral Research.40
Five years later the Belmont Report was released and endorsed by the United States as the
regulation of research of human subjects.41 The Belmont Report builds on the Nuremburg Code
and the Helsinki declaration.42 Regulations were developed in the United States to govern the
approval process involving the use of clinical trial data from outside the United States.43 For
domestic clinical trials, following the approval of the IND, human subjects must have provided
legally effective informed consent and the trial must be conducted in accordance with GCP.44

37

21 C.F.R. § 312.120 (2013).
OIG FOREIGN CLINICAL TRIALS REPORT supra note 7, at p 2.
39
Id.
40
See supra note 15.
41
Office of Human Subjects Research, Nat’l Insts. of Health, The Belmont Report: Ethical
Principles and Guidelines for the Protection of Human Subjects of Research, Apr. 18,
1979, http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html.
42
Id.
43
21 C.F.R. § 314 (2013); 21 C.F.R. § 312.120 (2013).
44
21 C.F.R. § 50.20 (2013); see supra note 11 and accompanying text.
38
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The FDA regulation of the use of foreign clinical data in submissions for drugs to be
approved in the United States is similar to the regulations for domestic trials. One difference, as
noted above in section A, is the acceptance of clinical data not conducted under an IND. 45
Instead the FDA requires that the NDA submission include information showing that the clinical
trial was conducted under the local equivalent to IND.46 The regulations require foreign clinical
trials, “be conducted in accordance with good clinical practice (GCP), including review and
approval by an independent ethics committee and informed consent from subjects.” 47 In addition
the clinical data submitted by the sponsor must show that it is applicable to the US population,
that the clinical trials were performed by clinical investigators with recognized competence, and
the data can be considered valid without an onsite inspection by the FDA, or if the FDA wants to
it can validate the data through an on site inspection or other means.48
As companies sought to increase their return on R&D investment by conducting clinical
trials in developing countries, the safety and ethics problems that confronted clinical trial
research in the developed countries did not go away, rather they followed sponsors to the
developing countries that provide fertile ground for clinical trial research.49
C. The Globalization of Clinical Trials

45

21 C.F.R. § 312.120 (2013).
U.S. DEP’T OF HEALTH & HUMAN SERV., GUIDANCE FOR INDUSTRY AND FDA STAFF:
FDA ACCEPTANCE OF FOREIGN CLINICAL STUDIES NOT CONDUCTED UNDER AN IND
FREQUENTLY ASKED QUESTIONS (Mar. 2012), [hereinafter 2012 FDA Guidance], available at
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM294729.pdf.
47
Id.
48
Id. at p 1.; 21 C.F.R. § 312.120 (2013).
49
See supra note 8 and accompanying texts; see also Seth W. Glickman et al., Ethical and
Scientific Implications of the Globalization of Clinical Research, 360 NEW ENG. J. MED. 816
(2009).
46

9

In the 1990’s research and development costs soared while the number of newly
approved drugs remained stagnant. 50 To improve their financial situation pharmaceutical
companies began to look for ways to redesign their approach to R&D.51 Soon, pharmaceutical
companies began to outsource aspects of the clinical process to third parties, with the goal of
lowering costs and increasing enrollment of human subjects by running clinical trials across the
globe.52
The rise of outsourcing has been a direct benefit to Contract Research Organizations
(CRO).53 CROs have lowered costs for pharmaceutical companies and continued the movement
of clinical trials to developing countries. 54 The FDA defines a CRO as a corporation that
assumes, as an independent contractor with the sponsor, one or more of the obligations of a
sponsor to design, select, monitor, evaluate, and/or prepare materials to be submitted to the
FDA.55 CROs’ services can provide a range of R&D functions needed by their clients as internal
departments have been cut due to downsizing. 56 Outsourcing during the drug development

50

See supra note 6 and accompanying texts.
DHANKAR ET AL., supra note 5.
52
See, Miriam Shuchman, Commercializing Clinical Trials--Risks and Benefits of the CRO
Boom, 357 N. ENG. J. MED. 1365, (Oct. 2007) (discussing the rise of contract research
organizations (CROs) due their ability to provide speed and efficiency in conducting clinical
trials).
53
Id. at 1366 (highlighting the growth in the CRO market from $7 billion in 2001 to $17.8
billion in 2007); see also Ed Silverman, Why Contract Research Organizations Are So Hot,
FORBES (Oct. 4, 2011, 7:31PM), http://www.forbes.com/sites/edsilverman/2011/10/04/whycontract-research-organizations-are-so-hot/.
54
Shuchman supra note 53 and accompanying texts.
55
21 C.F.R. § 312.2(b) (2013).
56
Kenneth Getz et al., Resizing the Global Contract R&D Services Market A new study revises
estimates of the market, CONTRACTPHARMA (May 30, 2012),
http://www.contractpharma.com/issues/2012-06/view_features/resizing-the-global-contract-rdservices-market/#sthash.j3CZyPyx.dpuf.
51

10

process has led to the CRO market to almost triple in size from $7 billion in 2001, to an
estimated 2014 size of $23.6 billion.57
Because CROs have been able to conduct efficient, fast paced trials for their partners,
they have largely replaced the academic institutions that were the traditional partners of
pharmaceutical companies in drug development.58 The participation of CROs and their effect on
clinical trial research has been lauded in the industry research world and criticized elsewhere.59
CRO’s have been questioned as contributing to research abuse in clinical trials in the United
States, Canada, and Britain. 60 At the same time CROs have been accused of also hindering
research as a result of over zealous enforcement of regulations.61

57

Shuchman supra note 53 and accompanying text; ISR Projects the 2014 CRO Market to Be
Worth $23.6 Billion, FIERCECRO (Feb. 10, 2014). http://www.fiercecro.com/press-releases/isrprojects-2014-cro-market-be-worth-236-billion-read-more-httpwwwdigitalj.
58
Shuchman Supra note 53, at 1366.
59
See Shuchman supra note 52 (acknowledging that CRO’s offer greater spend and efficiency
while questioning CRO reporting methods and commenting on the industry's tendency to
internalize problems); but see, Lutz Heinemann & Marcus Hompesch, Role of Physicians in the
Pharmaceutical Industry and Clinical Research Organizations: Take More Pride in Your Work,
2 Diabetes Sci Technol. 4, 707-709, Jul 2008, available at
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769751,(arguing Dr. Shuchman focused on
CRO related negative events while ignoring similar events in academia).
60
See Shuchman supra note 52, at 1368 (“SFBC International was cited by a Bloomberg report
as having inadequate oversight of a clinical trial location in Florida which led to SFBC settling a
shareholder class action lawsuit for $28.5 million…SFBC clinical trial in Montreal included a
patient with tuberculosis who remained in the trial and nine other trial participants eventually
tested positive for tuberculosis…CRO Parexel managed a clinical trial in Britain where subjects
taking the drug had organ failure and British regulatory agency found that the Parexel physician
involved in the study had inadequate training and Parexel had no formal system in place for
providing round-the-clock medical coverage.”); see also Elisabeth Rosenthal, When drug trials
go horribly wrong, N.Y.TIMES, Apr. 7, 2006, available at
http://www.nytimes.com/2006/04/07/world/europe/07iht-drug.html?pagewanted=all.
61
See Trudie Lang & Sisira Siribaddana, Clinical Trials have Gone Global: Is this a good
thing?, PLOSMEDICINE (June 2012),
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001228,
(discussing examples of “inappropriate clinical trial conduct that could be adversely impacted
by…overly keen CROs…can unnecessarily overburden and increase the cost of clinical trials”).
11

The results of outsourcing in R&D and the globalization of clinical trials were soon
realized in both developed and developing countries. Clinical data from trials conducted outside
of the United States is in over eighty percent of approved marketed drug applications by the
FDA.62 Less than half of all clinical trials are conducted in the United States. 63 This is the
combined result of research and development economic pressures, regulatory oversight of trials
conducted in the United States and the lack of willing research subjects. 64 Two large recipients
of the clinical trial migration are China and India.65 Recently, China has seen their clinical trial
market grow at a rate of 15%.66 While India initially saw remarkable growth in their clinical trial
market, recent safety and ethical concerns have derailed the industry and highlighted the risks for
sponsors and research subjects in conducing clinical trials in emerging markets.67 Still, the India
clinical trial market was recently valued at $450 million and is projected to increase in size to
over $1 billion.68

62

2010 HHS OIG Report, supra note 7, at p 10.
Id.
64
Kristen Brooks, CRO Outlook & Market Trends: Innovation tied to globalization &
collaboration, CONTRACTPHARMA (June 5, 2013), http://www.contractpharma.com/issues/201306/view_features/cro-outlook-market-trends/; Gregory Lopes, Drug Makers Look East For
Testing, WASH. TIMES, Dec. 8, 2007, (large populations in India and China provide a large pool
for companies to gather clinical data at a faster pace).
65
Report: Clinical trials market growing rapidly, CENTERWATCH (July, 5, 2011, 12:16PM),
http://www.centerwatch.com/news-online/article/1827/report-clinical-trials-market-growingrapidly#sthash.nTQlzCSn.dpbs.
66
Rajesh Jain, India’s clinical trials industry—in detraction mode, KPMG SECTOR INSIGHTS 25
(June 2012),
http://www.kpmg.com/IN/en/IssuesAndInsights/ArticlesPublications/kbuzz/Documents/KbuzzIssue-18.pdf.
67
Id.
68
Dinsa Sachan, Supreme court ruling brings clinical trials to a halt in India, ROYAL SOCIETY
OF CHEMISTRY, (Oct. 15, 2013) http://www.rsc.org/chemistryworld/2013/10/supreme-courtruling-clinical-trials-halt-india (discussing the Frost & Sullivan research report that estimated
that the India clinical trial industry was worth $450 million (£282 million) in 2011).
63

12

The globalization of clinical trials has been beneficial to the pharmaceutical industry, as
they have achieved the goal of lowering costs, increasing patient enrollment and avoided
complex regulatory burdens.69 This has coincided with industry investment in China and India
as companies looked to increase their presence and view the countries as not only a low cost
location, but also countries where drugs can be marketed and sold and thus lessen their reliance
on developed markets.70 However, both countries have suffered recent setbacks involving harm
to research subjects and questions on the validity of data from their clinical trials that stem from
their inadequate regulatory systems.71
This rise of clinical trials taking place outside the United States has presented unique
challenges to the FDA.72 As the FDA is responsible for dealing with the problem of regulating
the information that is obtained from clinical trials in developing countries to try to ensure the
protection of the human subjects where the research is taking place and that the information
obtained is valid when the data is submitted in a NDA, the need for increased international and
domestic regulations in partnership has risen.73
II. International Standards and Domestic Regulation of Clinical Trials
A. Nuremburg Code, Helsinki Declaration, Belmont Report and International
Conference on Harmonization

69

Seth W. Glickman et al., Ethical and Scientific Implications of the Globalization of Clinical
Research, 360 NEW ENG. J. MED. 816, 817 (2009), (“A pharmaceutical executive reported that
a first-rate academic medical center in India charges approximately $1,500 to $2,000 per case
report, less than one tenth the cost at a second-tier center in the United States.”) (“An important
force that is moving clinical trials to developing countries is the increasingly bureaucratic and
expensive regulatory environment in many wealthy countries.”).
70
Robert Cyran & George Hay, China’s Allure in Drug Research, N.Y.TIMES, December 7,
2011, at B2.
71
See supra notes 66 and 68 and their accompanying texts.; see also Katie Thomas, Drug
Research in China Falls Under a Cloud, N.Y.TIMES, July 22, 2013, at A1.
72
2010 HHS OIG Report supra note 7, at p 1.
73
21 CFR 314.106 (2013); See 2010 HHS OIG Report supra note 7, at p 21.
13

The International regulation of clinical trial research on human subjects began after
World War II. The Nuremburg Code was created following the completion of the Nuremburg
Trials that involved the prosecution of Nazi physicians for war crimes following the discovery of
their experiments on human research subjects.74 The ten principles from Nuremburg Code serve
as a blueprint for the ethical treatment of research subjects around the globe by requiring that
research participation by human subjects is voluntary and informed.75
The Declaration of Helsinki was adopted by the World Medical Association in 1964, “as
a statement of ethical principles for medical research involving human subjects, including
research on identifiable human material and data.” 76 The Declaration has subsequently been
reformed numerous times to reflect societal changes, with the latest revision occurring in 2013.77
At its core the Deceleration of Helsinki provides ethical principles for physicians and others
involved in human subject research to consider when conducting research with human subjects.78
Following the development of various regulations on clinical research across the globe,
each different than the next, it became apparent that there was a need for harmonization between

74

Evelyne Shuster, Fifty Years Later: The Significance of the Nuremberg Code, 337 NEW END. J.
MED.1436, (Nov. 13, 1997) available at
http://www.nejm.org/doi/full/10.1056/NEJM199711133372006.
75
The Nuremberg Code, reprinted in Trials of War Criminals Before the Nuremberg Military
Tribunals Under Control Council Law No. 10, Vol. 2, 181-82 (Government Printing Office
1949) (“The Nuremberg Code provides, inter alia: (1) subjects of medical experimentation must
provide voluntary, informed consent; (2) the experiment must yield socially useful results that
would not have been obtainable by other means; (3) the experiment should be conducted to
minimize risk to the subject; and (4) the experiment must be terminated if the researcher believes
that it may cause harm to the subject.,”) available at
http://www.hhs.gov/ohrp/archive/nurcode.html.
76
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI: ETHICAL PRINCIPLES FOR MEDICAL
REASRCH INVOLVING HUMAN SUBJECTS (2013),
http://www.wma.net/en/30publications/10policies/b3/.
77
Id.
78
Shuster supra note 74, at p. 1440.
14

the various regulations. 79

This led to the creation of the International Conference on

Harmonization (ICH).80 The ICH is a collaborative effort by regulatory authorities in the United
States, Japan and European Union that designs and recommends shared procedures and
regulations designed to safeguard the safety and efficacy of clinical research for new drugs. 81 In
1997 the FDA endorsed the GCP guidelines developed by the ICH for clinical trial research on
human subjects to be used as guidance to the FDA.82
While the globalization of clinical trials is over three decades old, public knowledge of
this shift began to make headlines in 2000 following a six part series published by the
Washington Post highlighting the practice and the ethical compromises that were made. 83 The
use of foreign clinical trials in developing countries has continued to make public headlines.84
Despite regulations designed to govern the use of foreign data, prevent harm to research subjects,

79

The Need to Harmonise, ICH http://www.ich.org/about/history.html (last visited Apr. 23, 2014)
(discussing the formation of the ICH between Europe, Japan and the United States).
80
Id.
81
Id.
82
Compare 21 C.F.R. § 312.120 (2013) (describing GCP as, “a standard for the design, conduct,
performance, monitoring, auditing, recording, analysis, and reporting of clinical trials in a way
that provides assurance that the data and reported results are credible and accurate and that the
rights, safety, and well-being of trial subjects are protected.”, with INT’L CONFERENCE ON
HARMONIZATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR
HUMAN USE, ICH (June 10, 1996),
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4
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and protect the public from unsafe drugs, the FDA was roundly criticized for its response to the
shifting locales of clinical trials and inability to monitor and inspect foreign clinical trials.85
The Nuremburg Code, The Helsinki Declaration, The Belmont Report, The FDA, The
EMEA and numerous other international agreements and regulatory bodies have all been in
effect during the past two decades.86 Nevertheless, clinical trials in China and India continue to
present risk of harm to human research subjects and the prospect of invalid data due to the weak
regulatory enforcement. 87

Subsequently the pharmaceutical industry has found itself in

numerous legal and ethical quandaries resulting from clinical trials where instances of abuse to
research subjects and invalid data continue to occur in part because of the major failing in
developing countries to enforce regulations.88
B. Clinical Trial Regulation in China
For the past quarter century China has been the economic medicine for the global
economy.89 This has been particularly true for the pharmaceutical industry.90 Since 2006 China
has grown from the ninth largest pharmaceutical market in world with sales of $27 billion, to
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currently the third largest pharmaceutical market in the world with sales over $70 billion. 91
China has also proven to be fertile ground for clinical trial research recruiting due to the size of
its population and the low cost of labor.92 An additional issue that is related to the growth of
clinical trials but not a driver, is that in order for a new product to gain regulatory approval in
China, the product’s clinical trials must have taken place in China.93 Thus a company looking to
gain market access in China must conduct clinical trial research in China first. This usually is in
the form of partnering with a Chinese company. These factors led to the growth in clinical trials
in China of 47%.94 By comparison the number of clinical trials conducted in the United States
during the same period has decreased by an average of 6.5% annually.95
In accordance with the market growth, China has developed and instituted numerous
regulations on clinical research that are inline with adopted international regulations. 96 The
China Food and Drug Administration (CFDA) is the equivalent of the FDA in China. The
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CFDA governs clinical trial research. 97

Chinese laws on clinical research refer to the

Declaration of Helsinki as the foundation for research involving human subjects. 98 China
requires that a research proposal be submitted to an ethical review committee where the proposal
is either accepted or rejected. 99 The CFDA also requires that GCP be followed in line with
international standards for human subject research.100 One major difference between the ICH
GCP guidelines and GCP in China is that the research subject is not required to sign the consent
form, only the investigator.101 Another major difference is that the Chinese ethics regulations are
not enforceable by law.102
Thus despite the presence of regulation requiring independent ethical review boards, and
other instruments to protect the research subjects and the trial outcomes, sponsors of clinical
trials in China are rarely punished through these regulations. However, recently clinical trial
outcomes in China have come under questioning based on accusations of fraud and bribery.103
Misconduct was recently discovered by a GlaxoSmithKline internal audit. The report
described a series of failures including the failure to report results from an animal study on a
product that was now being tested in human research subjects, the failure to record research
subject consent forms during clinical trials, the failure to track and document whether the
approved clinical trial protocol was being followed, and contained allegations concerning
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payments and kickbacks to the clinical investigators who were responsible for oversight of the
trials.104
Eventually GlaxoSmithKline fired their head of R&D in China over the clinical trial
accusations and was accused of paying over $490 million in bribes to increase sales.105 Soon
other allegations of corruption followed against other international pharmaceutical companies
and the United States notified pharmaceutical companies that it was under investigation for
violating the Foreign Corrupt Practices Act.106 Skeptics point out that the Chinese investigation
into the multinational pharmaceutical companies on bribery charges was in large part driven in
an effort to lower drug prices and increase the standing of domestic pharmaceutical
companies.107 These fears exist despite the subsequent bribery charges against one of China’s
largest pharmaceutical distributors.108 However other actions indicate that China may indeed be
serious about rooting out corruption in their pharmaceutical industry.
An example that focuses on the validity of clinical trial data in China occurred involving
a potential blockbuster for Bristol-Meyers Squibb.109 The FDA delayed the drug Eliquis in 2012
after Bristol-Meyers discovered that the clinical trial records at a site in China were tampered
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with in order to hide GCP violations involving the wrong medication being dispensed to human
research subjects. 110 A Bristol-Meyers employee ahead of a FDA site inspection ordered a
contract research employee from the contract research firm Pharmaceutical Product
Development to change the research data to hide the GCP violation.111 The contract research
employee reported the cover-up to her supervisors.112 Bristol-Meyers reported to the FDA that
research subjects were given the wrong medicine, data was secretly changed, and serious adverse
events were not reported.113 After the Bristol-Meyers reported the problems to the FDA, BristolMeyers and the FDA together removed the tampered clinical data, reanalyzed the valid clinical
data and found the final positive result was not affected.114
China has solid regulations in place that are largely similar to those in the United States
and European countries.115 The problem remains how to increase enforcement levels directed at
maintaining ethical clinical research while not creating an atmosphere where companies feel that
selective enforcement is taking place.
C. Clinical Trial Regulation in India
Like China, India has been a preferred location for sponsors of clinical trials. 116
Conducting a clinical trial in India involves half the cost of running a trial in the United States
and India’s large population allows for easier patient recruiting.117 During the past decade India
has been trying to catch up to the increase in clinical trials by amending and adopting
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regulations.118 Currently the regulation of clinical trials is the responsibility of the Central Drugs
Standard Control Organization (CDSCO), through the Drug Controller General (DCG) which
operates under Ministry of Health and Family Welfare (MoH and FW).119 Schedule Y of the
Drugs and Cosmetic Act requires that a clinical trial sponsor in India must submit an application
that is approved in writing by an Independent Ethics Committee and the DCG.120 The CDSCO
requires that the clinical trial be conducted in accordance with the approved protocol from the
DCG and in compliance with GCP.121 Continuing problems with clinical trial regulation in India
is that an audit certificate is not required and that previously the IECs were not required to be
registered with the CDSCO.122
Thus despite the regulations, violations continue to occur that show harm to research
subjects that have resulted in death and the prospect of invalid trial data.123 The growth in the
Indian clinical trial market has stopped and declined following a series of discoveries involving
the unethical treatment of research subjects and allegations of fraudulent data.124 From 2008 to
2011 there were over a thousand deaths reported of research subjects enrolled in clinical trials. 125
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These discoveries have spurred the call for reform.126 In July 2013 the National Institutes of
Health (NIH), the United States medical research agency, suspended all ongoing NIH sponsored
clinical trials in India as a result of the ongoing regulatory uncertainty. 127 The efforts culminated
in October 2013 when the top Indian Court stopped ongoing clinical trials until the approval
process was reviewed to see if protocol was followed when the clinical trials were approved.128
III. Proposals For Improving Clinical Trial Regulation Enforcement
As illustrated above, the adoption of regulation in developing countries has not
eliminated the concerns on the ethical research of human subjects and the ability to verify
clinical trial data.129 The risk of exploitation continues because of the inability at the local level
to enforce regulations. 130 In this section I propose a three-prong approach to improve local
regulation enforcement in order to prevent harm to research subjects and eliminate invalid
clinical trials.
The three-prong solution involves enforcement of existing FDA regulations, international
partnerships between regulatory bodies, and private peer to peer partnerships all with the focus
of enhancing local enforcement in order to prevent harm to research subjects eliminate invalid
data from clinical trial research.
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A. FDA Enforcement of Existing Regulations
As discussed above in part one, the FDA has existing regulation governing foreign
clinical data in submissions for drugs to be approved in the United States.131
In response to the globalization of clinical trials, the FDA responded with a large effort to
increase its presence globally by opening up offices around the globe with the intent of assisting
other regulatory agencies through joint-collaboration. 132 The FDA issued guidance for how
clinical trial sponsors and companies can comply with the requirements needed for acceptance of
foreign clinical data in a NDA for studies both conducted under an IND and not conducted under
and IND.133 The guidance highlights that the enacted regulations require foreign clinical trials
“be conducted in accordance with good clinical practice (GCP), including review and approval
by an independent ethics committee and informed consent from subjects.”134
With the regulations already in place, the question turns to how to increase enforcement.
Currently, the FDA is limited by its inability to mandate local regulatory agencies to enforce
FDA regulations and this problem is heightened when neither the FDA nor the local agency is
unaware that violations have occurred.135 The lack of training and expertise is one of the main
problems in developing countries.136 Even where a regulatory system exists similar to the United
States, like in India, the inability to provide adequate oversight exists because of lack of
expertise and knowledge at the local levels.
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However, similar systems allow for sponsors to understand what is required and develop
increased knowledge instead of having to spend time elsewhere that does not increase protection
of clinical trials. The same is true for the FDA partnering with developing countries to train local
regulatory workers and provide training for GCP. To correct this problem, the FDA can increase
direct enforcement through the increase in their budget, and training local parties to assist in
enforcement.137 The increase in regulatory knowledge following training will allow for greater
enforcement, as local parties begin to understand what is required and identify violations. In
addition, the FDA can train clinical trial investigators from around the world in coordination
with the risk based monitoring approach that was recently endorsed by the FDA for use by
sponsors of clinical trials.138
The risk-based monitoring approach is designed to prevent errors during clinical trials by
focusing on monitoring activities that directly effect error prevention based on risk analyses.139
The process of risk-based monitoring requires sponsors to, “identify critical data and
processes…perform risk assessment to identify and understand the risks that could affect the
collection of critical data or the performance of critical processes, and then develop a monitoring
plan that focuses on the important and likely risks to critical data and processes.” 140 To identify
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the risks in a clinical trial includes looking to the geographic location of the trial and
understanding the level of local clinical trial enforcement knowledge.141 The goal is to allow
sponsors to develop dynamic clinical trial oversight based on the risks of each study. 142
The risk-based approach includes both centralized monitoring and on-site monitoring.143
Centralized monitoring is the monitoring of a clinical trial by a sponsor at a location other than
where the clinical trial is taking place.144 Centralizing the monitoring process is viewed as a way
to increase oversight through statistical analyses.145 Centralized monitoring includes analyses of
the need of on-site visits based on when the risk analyses identifies, “sites with data
anomalies…high error rates, protocol violations, or dropouts relative to other sites”.146 In sum
the approach looks for outlier sites that can then be designated for a targeted on-site monitoring
approach.147
The risk-based approach will maximize the FDA’s resources by allowing for efficient
regulation enforcement to protect human research subjects and clinical data by having sponsors
focus on the high risk factors of clinical trials.148 Also the risk-based approach avoids the cost
and manpower questions that go with the call for increased FDA personnel in remote locations,
while at the same time enforcing the existing regulations designed to protect human subjects and
clinical data.149 The FDA can also increase the uptake of the risk-based approach by leveraging
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the locations where it does have an increased foreign presence and use its personnel and
available money to spend on training local regulators.150
To properly develop training partnerships and increase local regulator monitoring, there
needs to be a strengthening of the regulatory partnerships between the FDA and other domestic
regulatory groups.
B. Partnerships Between Domestic Regulatory Agencies
The FDA can use improved mechanisms to enforce existing regulations and achieve
proper oversight of clinical trials by creating regulatory partnerships at the domestic and the
international level. Regulatory partnerships between international countries first came out of the
ICH in order provide industry guidance for conducting research with human subjects.151 More
recently the FDA has entered into individual cooperating agreements with countries covering
technology sharing, capacity building, technical cooperation in an effort to harmonize
multilateral relations.152 These relationships can provide the knowledge and expertise sharing to
make all parties stronger in the monitoring of clinical trials.
To gain buy-in from developing countries it has to be shown how they will benefit from
the partnership and not be harmed for being seen as increasing regulation.

This can be

accomplished by discussions with developing countries that focus on the dual benefits of the
partnership.

As discussed, countries like India and China are quickly becoming large
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pharmaceutical consumers as well. Showing how a partnership can protect individuals on both
ends of the research spectrum, and how the risks that can occur when regulation breaks down far
outweigh the risk of loss from increased regulation, will be difficult. This is true for two of the
fastest growing pharmaceutical markets, India and China, are also two of the largest areas where
clinical trials are conducted and fear that increased regulation will hurt their economy. 153
However, as discussed, the increase in harm to research subjects and questions on the validity of
clinical data in India and China and their governments responses appear to open the opportunity
for partnering. Further the tools developed in a good partnership can also be used to partner with
new countries as the migration of clinical trials continues.
As discussed above in section A, the mechanisms for enforcement already exist. 154
Applying the regulations in the best, most efficient manner is what is needed. 155 Increased
regulatory enforcement by the FDA, along with partnerships between domestic regulatory
agencies will work together to put pressure on the industry to increase their level of selfregulation.
C. Peer to Peer Partnerships at Industry level
The biggest area for impact to prevent harm to research subjects and eliminate invalid
clinical trials is at the industry level. Self-regulation at the industry level is also the area that is
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most challenging.

The industry is already highly regulated and places strict reporting

requirements on sponsors of clinical trials.156
Sponsors of clinical trials are required by statute following the determination that the
investigational drug presents an unreasonable and significant risk to subjects to stop the trial and
notify the FDA.157 On paper this looks good, but in practice the results have been mixed.158 Due
to the high investment costs in R&D, the length of time associated with drug development and
the financial impact at stake, responsible parties have shown that they are likely to look to the
short term to recoup the R&D costs as soon as possible, at the risk of sacrificing the long-term
health of a company, and it is easy to see why as sales of products have far exceeded fines for
hiding clinical trial data and other regulatory violations.159
What must be done is showing the industry why it is to their benefit to actively
participate in preventing regulatory violations before they occur. The investment in compliance
costs upfront is offset by reduction in compliance costs when the overall level of compliance is
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raised.160 The example discussed earlier of BMS self-reporting GCP violation during a trial of a
blockbuster drug is a good example. 161 An alternate scenario can be imagined where the
violation was not reported, only for the violation to be discovered during the review process or
after approval.162 The harm could have caused a longer delay in the approval time or caused the
approved drug to be removed for the market. This would lead to a consumer loss in confidence
in BMS, and cast further doubt on the industry practice of conducting clinical trials in developing
countries. Instead, by reporting the violation, the approval time was only delayed nine months
and investor confidence in BMS was not substantially harmed.163
While the approach of not reporting has not been financially fatal, continued noncompliance will only raise the risk of permanent damage in developed and developing countries.
Increasingly companies are becoming aware of this risk as evidenced by the industries exit from
conducting clinical trials in India because of regulatory uncertainty.164 This is evidence of the
effort to lower R&D costs becoming potentially the culprit in alienating consumers from using
their products in the emerging markets where the industry is increasingly reliant on selling its
products.165
Companies will be skeptical as they continue to compete over market share in developing
countries. Further as new companies develop in these countries, they will not have the same
self-monitoring expertise as established players and can create a problem that ends up giving the
entire industry a black eye. The same goes for the large pharmaceutical companies who may be
160
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inclined to forego reporting a violation in the hopes of having potential revenues outweigh the
regulatory violation costs. 166 What is needed is formalized approach that facilitates the
understanding of the long-term benefits for industry stakeholders.
Organizations like the Association of Clinical Research Organizations (ACRO) and the
Pharmaceutical Research and Manufacturers of America (PHRMA) can bring together industry
participants to form agreements that work to increase compliance and self-report by sharing the
costs of training and education in the area of clinical research. To increase compliance ACRO
and PHRMA should explore membership agreements that place certain requirements on
companies and include penalties for when violations occur.
The potential for this area is already displayed by instances of companies self reporting
violations.167 A more formal agreement would put the industry on firmer ground when it comes
to the safety of clinical trial research and provide companies with incentive to cooperate.
Conclusion
The issue of protecting human research subjects and ensuring the validity of data from
clinical trials continues to follow the pharmaceutical industry. It has followed the industry to
each clinical trial location around the world. By looking at past mistakes the FDA, the
pharmaceutical industry and international regulatory agencies can work together to protect
human research subjects in clinical trials and ensure that the data outcomes are valid.
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